EWM
MYGN icon

Executive Wealth Management’s Myriad Genetics MYGN Stock Holding History

Executive Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-300
Closed -$8K – 549
2019
Q2 		$8K Buy
+300
New +$8.47K ﹤0.01% 657

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Executive Wealth Management's MYGN Position: Q3 2019 in Review

Executive Wealth Management sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 300 shares — an estimated $8K sold.

Executive Wealth Management first reported a position in MYGN in Q2 2019 and held it in 1 quarter. The position peaked at $8K in Q2 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

  • Executive Wealth Management reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
  • Executive Wealth Management sold 300 Myriad Genetics shares in Q3 2019, an estimated $8K.
  • Executive Wealth Management first reported a position in Myriad Genetics in Q2 2019 and held it in 1 quarter.
  • Executive Wealth Management's Myriad Genetics position peaked at $8K in Q2 2019.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Executive Wealth Management's 13F filing for Q3 2019, filed 30 Oct 2019.